Found: 50
Select item for more details and to access through your institution.
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer.
- Published in:
- Clinical Genitourinary Cancer, 2023, v. 21, n. 2, p. 230, doi. 10.1016/j.clgc.2023.01.001
- By:
- Publication type:
- Article
Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the ‘Australian guidelines for the management of cutaneous melanoma’.
- Published in:
- Australasian Journal of Dermatology, 2017, v. 58, n. 4, p. 274, doi. 10.1111/ajd.12662
- By:
- Publication type:
- Article
Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.897991
- By:
- Publication type:
- Article
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-25175-5
- By:
- Publication type:
- Article
Novel radionuclide therapy combinations in prostate cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231187202
- By:
- Publication type:
- Article
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231177018
- By:
- Publication type:
- Article
A community-based model of rapid autopsy in end-stage cancer patients.
- Published in:
- Nature Biotechnology, 2016, v. 34, n. 10, p. 1010, doi. 10.1038/nbt.3674
- By:
- Publication type:
- Article
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.
- Published in:
- Journal of Pathology, 2013, v. 229, n. 3, p. 422, doi. 10.1002/path.4140
- By:
- Publication type:
- Article
The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2020, v. 16, n. 6, p. 312, doi. 10.1111/ajco.13407
- By:
- Publication type:
- Article
Use of vemurafenib in a patient unable to swallow whole.
- Published in:
- Journal of Oncology Pharmacy Practice, 2016, v. 22, n. 5, p. 733, doi. 10.1177/1078155215603231
- By:
- Publication type:
- Article
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1051, doi. 10.1007/s10637-022-01253-3
- By:
- Publication type:
- Article
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 844, doi. 10.1007/s10637-019-00832-1
- By:
- Publication type:
- Article
PARP Inhibitors Mechanism of Action and Their Potential Role in the Prevention and Treatment of Cancer.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Spatial analysis with SPIAT and spaSim to characterize and simulate tissue microenvironments.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-37822-0
- By:
- Publication type:
- Article
Detection of cell-free microbial DNA using a contaminant-controlled analysis framework.
- Published in:
- Genome Biology, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s13059-021-02401-3
- By:
- Publication type:
- Article
Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis.
- Published in:
- Frontiers in Endocrinology, 2023, p. 1, doi. 10.3389/fendo.2023.1295865
- By:
- Publication type:
- Article
Increased Thyroidal Activity on Routine FDG-PET/CT after Combination Immune Checkpoint Inhibition: Temporal Associations with Clinical and Biochemical Thyroiditis.
- Published in:
- Cancers, 2023, v. 15, n. 24, p. 5803, doi. 10.3390/cancers15245803
- By:
- Publication type:
- Article
Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer.
- Published in:
- Cancers, 2022, v. 14, n. 23, p. 5922, doi. 10.3390/cancers14235922
- By:
- Publication type:
- Article
Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status.
- Published in:
- Cancers, 2022, v. 14, n. 16, p. 3947, doi. 10.3390/cancers14163947
- By:
- Publication type:
- Article
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.
- Published in:
- Cancers, 2021, v. 13, n. 10, p. 2334, doi. 10.3390/cancers13102334
- By:
- Publication type:
- Article
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab.
- Published in:
- NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00641-7
- By:
- Publication type:
- Article
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
- Published in:
- Journal of Translational Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12967-023-04607-4
- By:
- Publication type:
- Article
Genome-wide plasma DNA methylation features of metastatic prostate cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
The landscape of cell-free mitochondrial DNA in liquid biopsy for cancer detection.
- Published in:
- Genome Biology, 2023, v. 24, n. 1, p. 1, doi. 10.1186/s13059-023-03074-w
- By:
- Publication type:
- Article
A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [<sup>161</sup>Tb]Tb-PSMA-I&T.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.124.267650
- By:
- Publication type:
- Article
Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.243295
- By:
- Publication type:
- Article
Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.243295
- By:
- Publication type:
- Article
Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.243295
- By:
- Publication type:
- Article
Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 9, p. 1, doi. 10.2967/jnumed.120.243295
- By:
- Publication type:
- Article
Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.243295
- By:
- Publication type:
- Article
Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.236414
- By:
- Publication type:
- Article
Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 4, p. 517, doi. 10.2967/jnumed.118.219352
- By:
- Publication type:
- Article
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.
- Published in:
- Prostate, 2020, v. 80, n. 15, p. 1273, doi. 10.1002/pros.24056
- By:
- Publication type:
- Article
Establishing a cryopreservation protocol for patient‐derived xenografts of prostate cancer.
- Published in:
- Prostate, 2019, v. 79, n. 11, p. 1326, doi. 10.1002/pros.23839
- By:
- Publication type:
- Article
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 4, p. 1041, doi. 10.1007/s00280-013-2099-8
- By:
- Publication type:
- Article
ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration‐resistant prostate cancer treated with enzalutamide (ANZUP 1901)
- Published in:
- BJU International, 2021, v. 128, n. 5, p. 642, doi. 10.1111/bju.15491
- By:
- Publication type:
- Article
UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup>Lu‐PSMA‐617 and docetaxel vs docetaxel in metastatic hormone‐naïve prostate cancer (clinical trial protocol).
- Published in:
- BJU International, 2021, v. 128, n. 3, p. 331, doi. 10.1111/bju.15384
- By:
- Publication type:
- Article
Identification of single nucleotide variants using position-specific error estimation in deep sequencing data.
- Published in:
- BMC Medical Genomics, 2019, v. 12, n. 1, p. N.PAG, doi. 10.1186/s12920-019-0557-9
- By:
- Publication type:
- Article
Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data.
- Published in:
- Journal of Clinical Pharmacology, 2013, v. 53, n. 10, p. 1020, doi. 10.1002/jcph.140
- By:
- Publication type:
- Article
Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups.
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Patient-reported outcomes in melanoma survivors at 1, 3 and 5 years post-diagnosis: a population-based cross-sectional study.
- Published in:
- Quality of Life Research, 2020, v. 29, n. 8, p. 2021, doi. 10.1007/s11136-020-02464-y
- By:
- Publication type:
- Article
The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors.
- Published in:
- 2019
- By:
- Publication type:
- journal article
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2020, v. 47, n. 12, p. 2776, doi. 10.1007/s00259-020-04815-w
- By:
- Publication type:
- Article
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2020, v. 47, n. 10, p. 2322, doi. 10.1007/s00259-020-04723-z
- By:
- Publication type:
- Article
Envisioning the future of early anticancer drug development.
- Published in:
- 2010
- By:
- Publication type:
- research
Bevacizumab as a steroid‐sparing agent during immunotherapy for melanoma brain metastases: A case series.
- Published in:
- Health Science Reports, 2019, v. 2, n. 3, p. N.PAG, doi. 10.1002/hsr2.115
- By:
- Publication type:
- Article
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
- Published in:
- CA: A Cancer Journal for Clinicians, 2011, v. 61, n. 1, p. 31, doi. 10.3322/caac.20095
- By:
- Publication type:
- Article
Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-21576-8
- By:
- Publication type:
- Article